Pharmacological studies on resveratrol.
Kimura
Y
Y
Second Department of Medical Biochemistry, School of Medicine, Ehime University, Ehime, Japan. yokim@m.ehime-u.ac.jp
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D016718:Arachidonic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy; D005960:Glucosides / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015227:Lipid Peroxidation / Q000187:drug effects; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D008517:Phytotherapy; D028502:Polygonum; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D005960:Glucosides; D000960:Hypolipidemic Agents; D013267:Stilbenes; D016718:Arachidonic Acid; C094055:3,3',4-trihydroxystilbene; D000077185:Resveratrol; C058229:polydatin